Maralixibat is an ileal bile acid transporter (IBAT) inhibitor approved for the treatment of rare cholestatic liver diseases, including Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia. The gene discussed is SLC10A2; the disease is biliary atresia.